Stephan Moll, MD writes… A plain language summary for patients and interested public about homocysteine and the MTHFR mutations and their relevance in respect to blood clots was published today in the journal Circulation (link here).
Reference: Moll S, Varga EA. Homocysteine and MTHFR Mutations. Circulation. 2015;132:e6-e.
Stephan Moll, MD writes… The American Society of Hematology (ASH) is embarking on a program to develop clinically useful guidelines on the best management of patients with deep vein thrombosis or pulmonary embolism. ASH appropriately desires input from patients for the development of these guidelines. Any interested patient please see this letter from ASH explaining the goals of the project and what is needed.
Last updated: July 1st, 2015
Stephan Moll, MD writes… A clinical research study is being conducted in the U.S. for the treatment of chronic deep vein thrombosis (DVT) with post-thrombotic syndrome (PTS) and is open for enrollment. It is referred to as ACCESS-PTS. Read the rest of this entry »
Stephan Moll, MD writes: A drug in development (Idarucizumab) that reverses the blood thinner Pradaxa® (Dabigatran) is on a very promising path to get FDA approval in the next few months and be available for clinical use by the end of 2015.
Read the rest of this entry »
Stephan Moll, MD writes… A publication today in the journal Vascular Medicine discusses – for patients and family members – (a) in which patient with blood clots (DVT, PE) to consider testing for a clotting disorder, (b) what tests might be appropriate to do, (c) how the test results influence management with blood thinners, (d) what birth control methods are safe in women with history of blood clots or a clotting disorder, and (e) in which family members to consider thrombophilia testing (link here for the article).
Last updated: April 1st, 2015
Stephan Moll, MD writes…. Today (Jan 8th, 2015) the FDA approved yet another new oral blood thinner, Savaysa (edoxaban), for the treatment of DVT and PE. The drug was also FDA approved today for stroke prevention in patients with irregular heart beat (atrial fibrillation). The FDA press release here (link). Read the rest of this entry »
Stephan Moll, MD writes (Dec 17, 2014)… The American Society of Hematology (ASH) published last week two things that physicians dealing with DVT, PE and blood thinners should avoid [ref 1]. Read the rest of this entry »
Stephan Moll, MD writes (on Dec 8th, 2014)… A publication this week in the New England Journal of Medicine reports on a drug in development that protects patients from blood clots (DVT), without increasing the risk of bleeding. Too good to be true? Possibly, but may be not. Additional studies will have to tell. Read the rest of this entry »
Stephan Moll, MD writes (on12/5/2014)… Prevention of DVT and PE in patients who are in the hospital is important. Hospitals are required to have mechanisms in place that guarantee that patients at risk for DVT and PE get appropriate prophylaxis [reference]. We have developed at the University of North Carolina (UNC) a guidance document (link here; UNC VTE prophylaxis guidance document) as a resource for our doctors to assist in making decisions on which patients to give what type of DVT and PE prophylaxis. We are making this document available for other doctors and hospitals, to use it as is or modify it as needed.
Recommendations provided in this document are a reflection of current guidelines, clinical evidence, and UNC institutional initiatives. Patients may look at this document to see what kind of DVT prophylaxis might be appropriate in certain situations, such as surgeries; and they should discuss appropriate prophylaxis with their physicians. However, this document is not intended to replace individual patient evaluation and management decisions.
Joint Commission VTE measures (link here)
Last updated: Dec 5th, 2014
Stephan Moll, MD writes (on Nov 7th, 2014)… A publication this week in the New England Journal of Medicine reports on a new reversal agent (PER977 = Aripazine = ciraparantag) that may be effective against a number of different new oral anticoagulants [ref 1]. Read the rest of this entry »